Brian Rini, MD, on Key Practice Changing Abstracts in Prostate Cancer From 2021 ESMO
Brian Rini, MD, discussed abstracts presented during the 2021 ESMO Congress that will have an immediate impact on prostate cancer.
CancerNetwork® spoke with Brian Rini, MD, chief of clinical trials and professor of medicine at the Vanderbilt-Ingram Cancer Center, about intriguing abstracts presented at the 2021 European Society for Medical Oncology (ESMO) Congress. He mentioned a pair of abstracts in prostate cancer that will impact practice moving forward.
Transcription:
In prostate cancer, there were 2 studies presented that will change practice. One was called PEACE-1 (NCT01957436), which looked at triplet therapy versus doublet therapy in prostate cancer. [The trial compared] 2 different hormonal agents plus chemotherapy versus just 1 hormone agent plus chemotherapy and showed a survival advantage that will absolutely impact practice. And then another in the rising PSA setting, looking at double hormone therapy versus single hormone therapy that also showed great results. I think those will immediately change practice.
Reference
Fizazi K, Charles Galceran J, Foulon S, et al. A phase III trial with a 2x2 factorial design in men with de novel metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1. J Clin Oncol. 2021;39(no. 15_suppl):5000-5000. doi: 10.1200/JCO.2021.39.15_suppl.5000
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
